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a b s t r a c t
Chronic myelogenous leukemia (CML) is a cancer of the white blood cells that results from increased and
uncontrolled growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood.
The most common form of treatment for CML is imatinib, a tyrosine kinase inhibitor. Although imatinib is
an effective treatment for CML and most patients treated with imatinib do attain some form of remission,
imatinib does not completely eradicate all leukemia cells, and if treatment is stopped, all patients eventually
relapse (Cortes, 2005). In Kim (2008), the authors developed a mathematical model for the dynamics of CML
under imatinib treatment that incorporates the anti-leukemia immune response, and in Paquin (2011), the
authors used this mathematical model to study strategic treatment interruptions as a potential therapeutic
strategy for CML patients. Although the authors presented the results of several numerical simulations in
Paquin (2011), the studies in that work did not include the possibility of imatinib-resistant mutations or an
initial population of imatinib-resistant leukemia cells. As resistance is a signiﬁcant consideration in any drug
treatment, it is important to study the eﬃcacy of the strategic treatment interruption plan in the presence
of imatinib resistance. In this work, we modify the delay differential equations model of Kim (2008), Paquin
(2011) to include the possibility of imatinib resistance, and we analyze strategic treatment interruptions as
a potential therapeutic tool in the case of patients with imatinib-resistance leukemia cells.
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h. Introduction
Chronic myelogenous leukemia (CML) is a cancer of the blood
ells and bone marrow that causes uncontrolled growth of white
lood cells. In normal circumstances, the bone marrowmakes imma-
ure blood stem cells that progress to become mature blood cells.
n patients with CML, too many stem cells become white blood
ells (called granulocytes, or leukemia cells), due to increased and
nregulated growth of myeloid cells in the bone marrow. These
ells then accumulate in the blood and bone marrow, and pre-
ent development of healthy white blood cells, red blood cells, and
latelets [16].
Drug therapy programs for CML work by targeting the blood cells
hat contain the abnormal gene responsible for the overabundance
f diseased blood cells. In particular, drugs for CML work by target-
ng the protein produced by this gene, tyrosine kinase. The standard∗ Corresponding author. Tel.: +18057562679.
E-mail address: dpaquin@calpoly.edu (D. Paquin).
s
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b
greatment for CML is the tyrosine kinase inhibitor imatinib mesy-
ate (marketed as Gleevec or Glivec) [1]. Other targeted drugs for
ML treatment include dasatinib and nilotinib. Imatinib does effec-
ively treat CML, and most patients are able to attain some form of
emission with continuous, prolonged imatinib treatment. However,
matinib does not completely eradicate all leukemia cells, and if the
reatment is stopped, patients eventually relapse [4,11,15,17]. Addi-
ionally, acquired resistance to imatinib treatment poses a signiﬁcant
roblem for CML treatment programs [13,18].
In this work and in other landmark works on imatinib treatment
f CML [11,13–15,17], three standard types of remission are consid-
red: hematologic, cytogenetic, and molecular. Each type of remis-
ion corresponds to a 2-log, or 100-fold, decrease compared to the
revious level. According to Lowenberg [9], each patient typically has
pproximately 1012 leukemia cells prior to imatinib treatment. Thus,
ematologic remission corresponds to 1010 cells, cytogenetic remis-
ion corresponds to 108 cells, andmolecular remission corresponds to
06 cells. Assuming that the average person has approximately 6 L of
lood, these remission levels correspond to the concentration levels
iven in Table 1. With imatinib treatment, nearly all patients achieve
Table 1
Leukemia cell concentrations (in k/μL) corresponding to hematologic,
cytogenetic, and molecular remission levels.
Remission level Hematologic Cytogenetic Molecular
Concentration (k/μL) 1.67 1.67 × 10−2 1.67 × 10−4
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thematologic remission, and approximately 75% of patients achieve
cytogenetic remission [4,8,13].
Several mathematical models have been developed, simulated,
nd analyzed to study the the pathogenesis, effects, and dynamics of
matinib treatment of CML , including [6,7,11,14,17]. A review of sev-
ral mathematical models of CML and the clinical insights provided
y the models is contained in [13]. In all of the models referenced
bove, the authors conclude that imatinib does not completely elimi-
ate the leukemia cell population, and propose that imatinib therapy
hould be combined with an additional form of treatment. In [14],
he authors use a stochastic process model to simulate a competition
f normal and malignant stem cells for a common resource. In [11],
ichor et al. constructed a system of ordinary differential equations
o model the dynamics of CML with imatinib treatment. Their model
escribes the progression of leukemia cells through four different life
tages, and stipulates that the progression of leukemia cells from one
tage to another is slowed with imatinib treatment. Kim et al. modi-
ed this ODE model in [6] to construct a system of delay differential
quations that includes not only the progression of leukemia cells
hrough life stages, but also interactions of leukemia cells with anti-
eukemia T-cells. Their work indicates that the strength of a given
atient’s immune response may be an important factor in determin-
ng what type of remission the patient achieves, and how long the
atient remains in remission, while undergoing continuous imatinib
reatment.
In [12], Paquin et al. used the delay differential equations model
resented in [6] to study the effectiveness of strategic treatment in-
erruptions as a potential clinical approach to enhancing the effects of
matinib treatment forCML. Theauthorsdemonstrated that treatment
rograms that involve strategic treatment interruptions inwhich ima-
inib treatment is temporarily stopped in order to leverage the anti-
eukemia immune responsemayprevent leukemia fromrelapsingand
ay prevent remission for signiﬁcantly longer than continuous ima-
inib treatment, and, inmany cases, strategic treatment interruptions
ay completely eliminate leukemic cells from the body. They also
sed a series of numerical simulations to determine an optimal time
uring which imatinib treatment should be temporarily stopped in
rder to leverage the patient’s own anti-leukemia immune response.
owever, in [12], the authors did not consider the possibility of ima-
inib resistance. In particular, it was assumed that it is not possible
or patients to develop imatinib-resistant leukemia cells, and that
atients do not initially have any imatinib-resistant leukemia cells
rior to starting treatment. As acquired and innate drug resistance
re important considerations in any drug therapy program, the nat-
ral next step following the work in [12] is to study the possible
ﬃcacy of strategic treatment interruptions when the patient may
evelop imatinib resistance during treatment.
This paper is organized in the followingway.We begin in Section 2
y modifying the delay differential equations model to include the
ossibility of both pre-treatment imatinib-resistant cancer cells and
cquired imatinib resistance. We then derive estimates of the model
arameters using experimental data from [3]. We use the universal
odel parameter values (i.e. the parameter values that are the same
or all patients) from [6], and we focus on using the data from [3]
o derive new values of patient-dependent parameters in the case of
matinib resistance. In Section 3,we present and analyze the results of
everal strategic treatment interruption simulations in the presence
f imatinib resistance, and we conclude that the success of strate-
ic treatment interruptions in this case is largely dependent on thetrength of the patient’s immune response. In Section 4, we study the
ensitivity of the results to the universal and patient-speciﬁc param-
ters used in the model. Concluding remarks are in Section 5.
. A mathematical model for imatinib treatment of CML with
matinib resistance
In 2005, Michor et al. [11] constructed a differential equations
odel of CML based on the architecture of the hematopoietic system.
n particular, this model describes the development of leukemia cells
hrough four subsequent life stages. The different concentrations of
ell populations (in k/μL, i.e. thousands of cells permicroliter) at time
are denoted as follows: y0(t), leukemia stem cells; y1(t), progenitor
ells; y2(t), differentiated cells; and y3(t), terminally differentiated
ells. Leukemia cells progress through these different life stages in the
ollowing way. Stem cells regenerate themselves at rate ry. Stem cells
ecome progenitor cells at rate ay and die at rate r0. Progenitor cells
ecome differentiated cells at rate by and die at rate d1. Differentiated
ells become terminal cells at rate cy and die at rate d2. Terminal cells
die at rate d3. With imatinib treatment, ay and by are reduced by a
factor of 100 and 750, respectively, thus resulting in a decrease in the
overall leukemia concentration.
A second set z0, z1, z2, z3 (imatinib-resistant stem, progenitor, dif-
erentiated, and terminally differentiated) of leukemia cells was in-
luded in this model to account for the possibility of resistance to
matinib. It was assumed that only stem cells can acquire imatinib
esistance, and that mutations occur at a rate of u mutations per
ivision.
The system of ODEs that describes the mathematical model of
ichor et al. [11] is given below.
dy0
dt
= (ry(1 − u)− d0)y0, dz0
dt
= (rz − d0)z0 + ryuy0,
dy1
dt
= ayy0 − d1y1, dz1
dt
= azz0 − d1z1,
dy2
dt
= byy1 − d2y2, dz2
dt
= bzz1 − d2z2,
dy3
dt
= cyy2 − d3y3. dz3
dt
= czz2 − d3z3. (1)
Kim et al. modiﬁed the model of Michor et al. to include the anti-
eukemia immune response. In particular, Kim et al. used experimen-
al T-cell data from [3] to measure the immune response during ima-
inib treatment of CML. To include the dynamics of the anti-leukemia
-cell response in the mathematical model of CML, Kim et al. added
n additional term to each of the equations of the model of Michor
t al. to account for the interaction between cancer cells and T-cells
hat results in death of leukemia cells. In addition, Kim et al. added a
elay-differential equation dT
dt
to describe the evolution of the T-cell
opulation T during imatinib treatment. The mathematical model of
im et al. which includes the immune response and imatinib resis-
ance is given by the following:
dy0
dt
= (ry(1 − u)− d0)y0 − qCp(C, T)y0,
dy1
dt
= ayy0 − d1y1 − qCp(C, T)y1,
dy2
dt
= byy1 − d2y2 − qCp(C, T)y2,
dy3
dt
= cyy2 − d3y3 − qCp(C, T)y3.
dz0
dt
= (rz − d0)z0 + ryuy0,
Table 2
Estimates of parameters [6,11].
Parameter Description Estimate
λ Fractional adjustment constant 0.75
d0 Stem cell death rate 0.003 λ/day
d1 Progenitor cell death rate 0.008 λ
d2 Differentiated cell death rate 0.05 λ
d3 Terminal cell death rate λ
ry Stem cell regeneration rate 0.008/day
ay Stem cell growth rate 1.6 (without imatinib treatment)
1.6/100 (with imatinib treatment)
by Progenitor cell growth rate 10 (without imatinib treatment)
10/750 (with imatinib treatment)
cy Differentiated cell growth rate 100
rz Imatinib resistant mutation stem cell regeneration rate 0.023/day
az Imatinib resistant mutation stem cell growth rate 1.6
bz Imatinib resistant mutation progenitor cell growth rate 10
cz Imatinib resistant mutation differentiated cell growth rate 100
k Kinetic (mixing) coeﬃcient 1 (k/μL)−1 per day
p0 Probability that T-cell engages cancer cell 0.8
qC Probability that cancer cell dies from 0.75
qT Probability that T-cell survives encounter with cancer cell 0.5
τ Duration of one T-cell division 1 day
n Average number of T-cell divisions Patient-dependent
dT Anti-leukemia T-cell death rate Patient-dependent
sT Anti-leukemia T-cell supply rate Patient-dependent
cn Decay rate of immune responsivity Patient-dependent
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dt
= azz0 − d1z1,
dz2
dt
= bzz1 − d2z2,
dz3
dt
= czz2 − d3z3,
dT
dt
= sT − dTT − p(C, T)C + 2np(Cnτ , Tnτ )qTCnτ , (2)
here
(C, T) = p0e−cnCkT, C =
3∑
i=0
yi,
nτ = C(t − nτ), Tnτ = T(t − nτ).
The cancer cell concentrations yk and zk in thismodel are the same
s those in the model of Michor et al. The new variable C represents
he total concentration of all leukemia cells, and the new variable T
epresents the concentration of anti-leukemia T cells. The ﬁnal terms
Cp0e
−cnCkTyi in each
dyk
dt
equation follow the law of mass action,
here kTyi describes the rate of interaction between anti-leukemia
-cells and the leukemia cell subpopulation yi, and k is the mixing
oeﬃcient. The coeﬃcient p0 is the probability that a T-cell engages
he cancer cell upon interaction, and qC is the probability that the
ancer cell dies from the T-cell response. Additionally, although the
recise mechanism of down-regulation is unknown, it is known that
eukemia cells suppress the anti-leukemia T-cell immune response.
his model describes this suppression by modeling the probability
hat a T-cell engages a cancer cell as exponential decay as a function of
he cancer concentration. Thus, the probability of that a T-cell engages
ith and kills a cancer cell is given by p0e
−cnC , where cn is the rate of
xponential decay due to down-regulation.
In the DDE dT
dt
, the parameter sT is the constant supply rate of
-cells, the parameter dT is the natural death rate of T-cells, and
(C, T)C is the rate at which T-cells engage leukemia cells and commit
o n rounds of division. The ﬁnal term represents the growth of the T-
ell population due to division, where τ is the average duration of one
ivision, and qT is the probability that a T-cell survives the encounter
ith an activated leukemia cell. Finally, Cnτ and Tnτ are the total can-er andT-cell concentrations at time t − nτ , respectively. Once a T-cell
egins the division process, it exits the collection of active T-cells and
e-enters the system nτ time units later after n divisions.
The estimated values of the universal parameters for this system
re given in Table 2 (and are taken from [11] and [6]). The parameters
, sT , dT , and cn are patient-dependent parameters, and in [6] the
uthors used experimental data from Chen et al. [3] to estimate these
alues for particular patients in the case without imatinib resistance,
.e. u = 0 and z0(0) = 0. We will study three patients, labelled P1, P4,
nd P12, in detail, as these were the patients in the Chen et al. study
ith the most available data.
In this work, we use the cancer and T-cell data from Chen et al.
3] to derive new values for these patient-dependent parameters in
he presence of imatinib resistance. In particular, we set the initial
oncentration z0(0) to 10
−9 (k/μL), which corresponds to an initial
esistant stem cell count of approximately 10 cells, and we set u,
he rate of imatinib-resistant mutations, equal to 4 × 10−8 mutations
er division. We also note, however, that mathematical modeling
nd data analysis in [18] suggests that u may be as high as 10−4,
nd in future work, we plan to incorporate the models of that work
nto our modeling work. Using the T-cell data presented in [3] and
nown information from the immunological literature [2,5,9] about
easonable ranges for the parameters, we simulated the DDE model
o obtain new values for the patient-dependent parameters for P1, P4,
nd P12 in the presence of imatinib resistance. These new parameter
alues are the primary difference between this model and the studies
resented in [6] and [12], as those studies ignored the possibility of
matinib resistance. Our goal in this work is to evaluate the potential
ﬃcacy of strategic treatment interruptions as an alternative therapy
rogram for CML treatment in the presence of imatinib resistance.
he values of these newly-derived patient-dependent parameters are
resented in Table 4.
Finally, steady-state conditions are used to obtain the initial con-
itions, as described in Table 3.
In Fig. 1, we illustrate the graphs of the solutions of the delay-
ifferential equations mathematical model 2 with the estimated val-
es of the universal and patient-dependent parameters for P1, P4,
nd P12, along with the measured data points from [3], in the case
f both initial imatinib resistance and a non-zero resistance muta-
ion rate. These solutions represent continuous imatinib treatment.
Table 3
Initial leukemia and T-cell concentrations [11].
Population Value
(
k
μL
)
Population Value
(
k
μL
)
y0(0) Patient-dependent z0(0) 1 × 10−9
y1(0)
ayy0(0)
d1
z1(0)
azz0(0)
d1
y2(0)
byy1(0)
d2
z2(0)
bzz1(0)
d2
y3(0)
cyy2(0)
d3
z3(0)
czz2(0)
d3
T(0)
sT
dT
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Fig. 1. Model solutions of system (2) ﬁt to T-cell data for patients P1 (top), P4 (middle),
and P12 (bottom) in the presence of initial imatinib resistance and non-zero imatinib
resistance mutation rate. The numerical values of the parameters are those in Tables 2
and 4.As illustrated in Fig. 1, and as discussed extensively in [6] and [12] (in
he case without imatinib resistance), continuous imatinib treatment
oes not completely eliminate leukemia, and all patients eventually
elapse with continuous imatinib treatment. Additionally, this model
ith imatinib resistance predicts an earlier relapse with continuous
matinib treatment as compared to themodel simulations that do not
nclude resistance in [6] and [12], as expected.
In [6] and [12], the ﬂuctuations that occur in the anti-leukemia
-cell concentrations corresponding to ﬂuctuations that occur in the
eukemia cell concentrations are discussed in great detail. The key
bservations are as follows:
• Initially, theT-cell concentrations are low, as the immune response
is nearly fully repressed by leukemia.
• As imatinib treatment begins to take effect, the leukemia cell con-
centrations decrease, and the patient’s immune response is even-
tually stimulated and the T-cell concentrations increase.
• As the patient’s immune response combines with imatinib treat-
ment to combat leukemia, the leukemia cell concentrations de-
crease, and eventually the T-cells are no longer stimulated and
their concentration begins to decrease.
From these observations, we conclude that there is a critical time
period during which the patient’s immune response is maximally ac-
tivated, and we seek to devise treatment strategies that optimally
leverage the immune response. In [12], the authors studied a wide
range of strategic treatment interruptions (STIs) in which imatinib
treatment is temporarily stopped in order to stimulate the immune
response. The length and starting time of the treatment interruption
were varied, and the authors measured the maximum leukemia con-
centration observed after the STI is administered, the minimum total
leukemia concentrationobservedduring treatment, the time required
for thepatient to achieve cytogenetic remission, and the time required
for total cancer elimination (if total elimination occurs). However, the
authors did not consider the possibility of imatinib resistance in the
initial study.
3. Results
In this work, we study the eﬃcacy of numerous strategic treat-
ment interruption simulations in which we incorporate acquired
(u = 4 × 10−8 mutations per division) and innate imatinib resistance
(z0(0) = 1 × 10−9 k/μL). In Fig. 2, we plot the leukemia and T-cell
concentrations for each patient for 0 ≤ t ≤ 50 months, with a 15-day
STI starting at time t = 6 months (t = 180 days). We observe that
interrupting imatinib treatment results in a 5-fold increase in T-cell
concentration as compared to continuous imatinib treatment.
As in [12], we also note that, as a result of the stoppage of ima-
tinib treatment from t = 180 to t = 195 days, there is a fast rise in the
concentration of leukemia cells while imatinib treatment is stopped.
However, this increase does not reach the initial level of leukemia
cells present in the patient prior to beginning imatinib treatment.
For example, for patient P1, the maximum leukemia concentration
Fig. 2. Leukemia and T-cell concentrations obtained by simulating themodel in system
(2) for P1, P4, and P12 for 0 ≤ t ≤ 1500 days with a 15-day STI from t = 180 to t = 195
days with imatinib resistance.
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uttained after imatinib treatment is stopped is 11.00 k/μL; the initial
re-treatment leukemia concentration for patient P1 is 73.0 k/μL.
or all patients, the increase in leukemia concentration that occurs
ollowing the stoppage of imatinib treatment does not approach the
nitial pre-treatment leukemia concentrations. See Table 4 for thepre-
reatment leukemia concentrations for each patient. Once imatinib
reatment is restarted, the leukemia concentration decreases rapidly,
nd for patients P1 and P4, leukemia is completely eliminated as a
esult of the STI. We also note that the peaks after treatment is inter-
upted are higher than the peaks in the non-resistant case discussed
n [12], so studying the effects of imatinib resistance is an important
onsideration when evaluating strategic treatment interruptions as a
ossible alternative therapy program for CML patients.
In Tables 5–7, we present the results of several 15-day treatment
nterruptions for patient P1, P4, and P12 with varying starting times.
or each STI, we report the maximum leukemia concentration ob-
erved after the STI is administered, the minimum total leukemia
oncentration observed during treatment, the time required for the
atient to achieve cytogenetic remission, and the time required for
otal cancer elimination (if total elimination occurs), as in [12].
Although patients P1 and P4 achieve complete leukemia elimina-
ionwith several 15-day strategic treatment interruptions (aswas the
ase in [12] without imatinib resistance), we observe that patient P12
ever achieves leukemia elimination with any 15-day STI. The min-
mum leukemia concentrations presented in Tables 5–7 are much
igher than the minimum leukemia concentrations that are achieved
n [12] in which imatinib resistance is ignored. Thus, a patient with
esistant cells will have a lower chance of complete elimination than
patient with no imatinib-resistant leukemia cells.
The observation that patient P12 does not attain leukemia elim-
nation with any 15-day STI represents a signiﬁcant difference from
he results obtained in [12] without imatinib resistance, as all pa-
ients achieved leukemia elimination with a 15-day STI when the
ossibility of imatinib resistance was ignored. Thus, the case of pa-
ient P12 illustrates the importance of considering the possibility of
nnate and/or acquired imatinib resistance. Patient P12 has an initial
eukemia concentration that is an order of magnitude greater than
he initial concentrations of the other two patients; we believe that
his may be an important factor that affects whether or not leukemia
an be eliminated with a single treatment interruption. We also note
but do not include the numerical results here) that patient P12 also
oes not achieve elimination with any 30-day or 45-day STI.
However, two well-timed strategic treatment interruptions do
ead to leukemia elimination for patient P12. As illustrated in Fig. 3,
f we interrupt imatinib treatment at t = 150 days for 30 days and
gain at t = 390 days for 60 days, patient P12 will reach a minimum
eukemia concentration of 1.40 × 10−6 k/μL,which is below the elim-
nation criteria. In Fig. 3, we observe two peaks of leukemia cells and
wo corresponding T-cell peaks, corresponding to the two separate
reatment interruptions.
These results illustrate that strategic treatment interruptions may
resent a viable alternative therapyprogram for chronicmyelogenous
eukemia, even when the patient has an initial count of imatinib-
esistant leukemia cells and/or a non-zero resistance mutation rate.
owever, as indicated by the results for P12, the patient-dependent
arameters play an important role in whether or not leukemia can be
liminated, and more than one treatment interruption and/or inter-
uptions of various durationsmay be required to achieve elimination.
n the future, we plan to study this optimization problem in more
etail as a formal optimal control problem.
. Sensitivity analysis
To study the sensitivity of our results on the numerical val-
es of the parameters and patient-dependent initial conditions in
Table 4
Values of patient-dependent parameters obtained with imatinib-resistant mutations and initial
imatinib-resistant cells: u = 4 × 10−8 mutations per division and z0(0) = 1 × 10−9 k/μL. These
new values represent a major advancement of this work, as earlier work with this model in [6] and
[12] did not consider the possibility of imatinib resistance.
Patient n dT sT cn y0(0) Initial total leukemia
concentration (k/μL)
P1 1.195 0.0016 2.28 × 10−6 0.85 7.6 × 10−6 73.0
P4 1.495 0.0033 1.34 × 10−6 2.00 2.4 × 10−6 23.1
P12 1.1685 0.007 3.08 × 10−5 0.80 1.2 × 10−5 116.8
Table 5
Results of several 15-day STI plans for patient P1 with imatinib resistance.
Treatment Maximum leukemia Minimum Time until Time until
plan: ﬁrst concentration leukemia cytogenetic total cancer
day of (k/μL) after STI concentration remission elimination
15-day STI is administered (k/μL) (days) (days)
No STI n/a 3.70 × 10−3 278 n/a
90 20.61 at t = 106 1.40 × 10−3 339 n/a
120 17.22 at t = 136 6.67 × 10−6 310 n/a
150 14.29 at t = 166 4.07 × 10−10 307 n/a
180 11.00 at t = 196 1.22 × 10−13 317 730
210 7.91 at t = 227 7.06 × 10−16 331 639
240 5.55 at t = 257 3.16 × 10−17 348 613
270 3.92 at t = 287 2.09 × 10−17 368 624
300 2.83 at t = 317 3.24 × 10−16 278 675
330 2.11 at t = 347 3.07 × 10−14 278 770
360 1.62 at t = 377 3.58 × 10−12 277 933
390 1.28 at t = 407 2.30 × 10−10 277 n/a
t
u
t
u
e
I
r
t
c
s
t
pTables 2 and 4 on the effectiveness of the strategic treatment in-
terruption strategies that we considered in Section 3, we apply the
Latin Hypercube sampling (LHS) method described in [10]. The LHSTable 6
Results of several 15-day STI plans for patient P4 with imatin
Treatment Maximum leukemia Maximum
plan: ﬁrst concentration T-cell
day of (k/μL) after STI concentration
15-day STI is administered (k/μL)
No STI n/a 1.75 × 10−2 at t = 3
90 6.52 at t = 106 2.90 × 10−2 at t = 3
120 5.45 at t = 136 6.19 × 10−2 at t = 2
150 4.55 at t = 166 1.09 × 10−1 at t = 2
180 3.59 at t = 196 1.46 × 10−1 at t = 3
210 2.72 at t = 227 1.71 × 10−1 at t = 3
240 2.02 at t = 257 1.86 × 10−1 at t = 3
270 1.51 at t = 287 1.89 × 10−1 at t = 3
300 1.15 at t = 317 1.78 × 10−1 at t = 3
330 0.89 at t = 347 1.59 × 10−1 at t = 4
360 0.71 at t = 377 1.37 × 10−1 at t = 4
390 0.57 at t = 407 1.17 × 10−1 at t = 4
Table 7
Results of several 15-day STI plans for patient P12 with imati
Treatment Maximum leukemia Maximum
plan: ﬁrst concentration T-cell
day of (k/μL) after STI concentration
15-day STI is administered (k/μL)
No STI n/a 3.13 × 10−2 at t = 2
90 32.53 at t = 106 3.29 × 10−2 at t = 2
120 27.03 at t = 136 4.73 × 10−2 at t = 2
150 21.35 at t = 166 7.71 × 10−2 at t = 3
180 13.84 at t = 196 1.05 × 10−1 at t = 3
210 7.66 at t = 227 1.23 × 10−1 at t = 3
240 4.23 at t = 257 1.25 × 10−1 at t = 3
270 2.54 at t = 287 1.04 × 10−1 at t = 3
300 1.69 at t = 317 7.68 × 10−2 at t = 3
330 1.24 at t = 347 5.68 × 10−2 at t = 4
360 0.987 at t = 377 4.35 × 10−2 at t = 4
390 0.838 at t = 407 3.48 × 10−2 at t = 4technique provides a method for simultaneously sampling a wide
range of parameters and statistically determining the correlation be-
ween the values of the parameters and various outcomes. We sim-
late the delay-differential equation model with various strategic
reatment interruptions with randomly sampled sets of parameters;
sing LHS, the values of the parameters are chosen in such a way that
ach parameter is well-distributed over its range of possible values.
n particular, the parameters are sampled uniformly to include the
anges of the parameter values for all patients analyzed in [3], as indi-
cated in Table 9. We vary every parameter and initial condition used
in the model. We perform 500 simulations of strategic treatment in-
terruptions for 15 days for each patient. Times at which the STIs start
are t = 90 to t = 390 days in 30-day increments.
In Table 8, we report the fraction of LHS samples that result in a
successful treatment. A success is deﬁned as a simulation in which
the total cancer concentration falls below 10−10k/μL (i.e. a simula-
ion in which the cancer concentration falls below the elimination
riterion). We observe a bell-shaped pattern for each patient; peak
uccess rates are for 15-day STIs that start at month 7, 6, and 5 for pa-
ients P1, P4, and P12 respectively. This pattern is due to timing of the
eak T-cell expansion rate in conjuction with T-cell stimulation viaib resistance.
Minimum Time until Time until
leukemia cytogenetic total cancer
concentration remission elimination
(k/μL) (days) (days)
54 5.60 · 10−3 252 n/a
44 1.40 · 10−3 301 n/a
94 1.11 · 10−5 279 n/a
92 4.52 · 10−9 282 n/a
04 7.14 · 10−12 295 688
20 7.94 · 10−14 312 581
38 4.55 · 10−15 330 557
60 2.47 · 10−15 252 573
84 1.53 · 10−14 252 617
11 4.39 · 10−13 252 702
40 1.92 · 10−11 252 870
70 6.38 · 10−10 252 n/a
nib resistance.
Minimum Time until Time until
leukemia cytogenetic total cancer
concentration remission elimination
(k/μL) (days) (days)
10 2.80 × 10−3 246 n/a
81 3.80 × 10−3 320 n/a
95 1.10 × 10−3 319 n/a
03 7.05 × 10−5 316 n/a
11 4.27 × 10−6 320 n/a
20 5.66 × 10−7 327 n/a
33 2.88 × 10−7 339 n/a
54 1.53 × 10−6 246 n/a
81 1.49 × 10−5 246 n/a
10 8.48 × 10−5 246 n/a
49 2.70 × 10−4 246 n/a
69 5.79 × 10−4 246 n/a
Fig. 3. Leukemia and T-cell concentrations for P12 for 0 ≤ t ≤ 1050 days with two STIs, one from t = 150 to t = 180 days and a second from t = 390 to t = 450 days.
Table 8
Fraction of LHS samples that result in a successful treatment. A success is deﬁned
as a simulation in which the total cancer population falls below 10−10k/μL.
Treatment Fraction of Fraction of Fraction of
plan: successful successful successful
start of 15-day STI treatments: P1 treatments: P4 treatments: P12
90 0.386 0.320 0.296
120 0.440 0.396 0.346
150 0.474 0.460 0.360
180 0.512 0.492 0.340
210 0.520 0.474 0.308
240 0.502 0.434 0.296
270 0.462 0.400 0.278
300 0.446 0.368 0.274
330 0.408 0.274 0.256
360 0.382 0.274 0.260
390 0.368 0.264 0.256
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Table 9
Sensitivity analysis of parameters performed for patient P1 for a 15-day
strategic treatment interruption from t = 210 to t = 225. For each param-
eter, we report the estimate of the parameter, the range used for Latin
Hypercube sampling, and the Pearson product-moment correlation (PPMC)
coeﬃcient between the parameter and the minimum cancer concentration.
To obtain the correlation coeﬃcients, we performed 1000 simulations in
which every parameter was varied over the given range.
Parameter Estimate Range PPMC
λ 0.75 0.5 to 1 −0.3577
d0 0.003λ/day ±25% −0.2768
d1 0.008λ ±25% −0.3265
d2 0.05λ ±25% −0.3725
d3 λ ±25% −0.3190
ry 0.008 ±25% 0.0486
ay 1.6 without imatinib ±25% 0.0385
1.6/100 with imatinib
by 10 without imatinib ±25% 0.0658
10/750 with imatinib
cy 100 ±25% −0.0062
rz 0.01 ±25% 0.1233
az 1.6 Same as ay 0.0385
bz 10 Same as by 0.0658
cz 100 Same as cy −0.0062
u 4 · 10−8 4 · 10−8 to 8 · 10−8 −0.0076
k 1 (k/μL)−1/day ±25% −0.0544
p0 0.8 ±25% −0.0011
qC 0.75 ±25% −0.0019
qT 0.5 ±25% −0.3187
τ 1 day 12–24 hours −0.0163
n 1.195 ±25% −0.2420
dT 0.0019/day ±25% −0.0087
sT 2.28 · 10−6k/μL /day ±25% 0.0379
cn 0.85 ±25% −0.0050
y0(0) 7.6 · 10−6 ±25% 0.0628
T(0) 0.0012 ±25% −0.0419
z0(0) 1 · 10−9 ±25% 0.0225
5
g
qn STI, and in future work we will investigate this relationship more
ormally.
We also provide in Table 9 the Pearson product-moment correla-
ion (PPMC) coeﬃcient between each parameter and the minimum
ancer concentration for patient P1 attained during the course of
reatment with a 15-day STI. To obtain the correlation coeﬃcients in
able 9, we performed 1000 LHS simulations with a strategic treat-
ent interruption from t = 210 to t = 225days after the start of treat-
ent, and we note that the correlation coeﬃcients obtained with all
ther single-interruption STI strategies considered in Section 3 are
omparable.
We observe that n and qT are negatively correlated with the min-
mum leukemia concentration. This negative correlation occurs be-
ause the T-cell population expands primarily through interaction
ith cancer cells, as described by the term 2np(Cnτ , Tnτ )qTCnτ in the
DEmodel.We also observe that the birth rate rz of imatinib-resistant
eukemia cells is correlated with the minimum leukemia concentra-
ion by an order of magnitude greater than any other birth rate. This
uggests that imatinib-resistant cells play a key role in the effective-
ess of an STI.. Conclusions
In this paper, we have presented the results of numerous strate-
ic treatment interruption simulations for CML patients with ac-
uired or developed imatinib resistance. Our results demonstrate that
[[
[
[
[
[
[
[CML can be eradicated evenwith pre-existing imatinib-resistant cells
and a non-zero imatinib-resistance mutation rate. As expected, we
achieved lower leukemia elimination success rates as compared to
the case without imatinib resistance studied in [12]. In two of the
three patients that we studied in this work, onewell-timed STI can be
enough to completely eliminate leukemia; in one patient, two well-
timedSTIswere required. Thisworkdemonstrates that imatinib resis-
tance is an important consideration when studying STIs as a possible
tool for improving treatment of CML, as the results that we obtained
here varied signiﬁcantly from those obtained without resistance in
[12]. The important question remains when to start and end the STI,
and how many STIs are required to successfully cure CML with ima-
tinib. It is clear from the sensitivity analysis conducted in Section 4
that the effectiveness of any STI treatment strategy relies on the nu-
merical values of the parameters and initial leukemia concentration
levels, including resistant cells and resistancemutation rates. Thus, in
a given course of treatment, it is important to estimate the values of
these parameters as early and as accurately as possible to implement
an STI to optimally leverage the patient’s anti-immune response. We
should also note that althoughwe do conduct a sensitivity analysis on
the parameters used in the model (both the patient-dependent and
universal parameters), the primary results in this paper are limited in
scope in that our results are based on data from only three patients.
Still, this work provides a framework for studying strategic treatment
interruptions as a possible therapeutic option for individual patients,
and this work demonstrates that such treatment programs have the
potential to eliminate leukemia, even in the presence of imatinib re-
sistance.
In futurework,we plan to study the optimization problems of how
many STIs should occur andwhen they should begin and end inmore
detail. In particular, we wish to analytically determine the optimal
STI strategy for a given patient based on the speciﬁc values of the
patient’s numerical parameters. We also plan to study the stability
of this DDE model in the presence of imatinib resistance. Finally, in
this work, we studied the dynamics of the immune response when
CML is treated with a single drug; in the future, we plan to study
the immune response and possible alternative treatment strategies
when additional drugs (such as dastainib or nilotinib) are used in
conjunction with imatinib.
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